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Abstract
We have examined the mucosal changes occurring in bronchial
biopsies from six atopic asthmatics 5-6 h after local endobron-
chial allergen challenge and compared them with biopsies from
saline-challenged segments from the same subjects at the same
time point. All the subjects developed localized bronchocon-
striction in the allergen-challenged segment and had a decrease
in forced expiratory volume in 1 s (FEV 1) (P < 0.01) and a
decrease in their methacholine provocative concentration of ag-
onist required to reduce FEVY from baseline by 20% (P < 0.05)
24 h postchallenge. At 6 h we observed an increase in neutro-
phils (P = 0.03), eosinophils (P = 0.025), mast cells (P
= 0.03), and CD3+ lymphocytes (P = 0.025), but not in CD4+
or CD8+ lymphocyte counts. We also detected an increase in
endothelial intercellular adhesion molecule type 1 (P < 0.05)
and E-selectin (P< 0.005), but not vascular cell adhesion mole-
cule type 1 expression with a correlative increase in submucosal
and epithelial LFA+ leucocytes (P < 0.01). Thus, in sensitized
asthmatics, local endobronchial allergen instillation leads to an
increased inflammatory cell infiltrate of the airway mucosa that
involves upregulation of specific adhesion molecules expressed
on the microvasculature. (J. Clin. Invest. 1994. 93:1411-
1421.) Key words: allergen * asthma * leukocytes * adhesion
molecules
Introduction
Autopsies (1) and more recently bronchoscopy findings (2)
have provided evidence for a major role of inflammation in-
volving many cells, including mast cells and eosinophils, in the
airway dysfunction that characterizes asthma. In addition to
showing an inflammatory infiltrate (3), bronchial mucosal
biopsies reveal epithelial damage (2, 4, 5) and subepithelial
collagen deposition (6). While some have found a correlation
between epithelial disruption (2), mast cell activation (3), eo-
sinophil (7), and T-cell infiltration (8) with indices of disease
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activity including bronchial hyperresponsiveness (BHR), ' it is
not possible to assess cellular dynamics at a single time point.
Almost a quarter ofa century has passed since Booij-Noord
et al. (9) and Pepys and Hutchcroft (10) described two phases
of airflow obstruction after allergen provocation of sensitized
asthmatic airways. The early asthmatic response (EAR) begins
almost immediately after allergen challenge, peaking at 15-20
min and recovering over 1-2 h. Its IgE dependence ( 1 1, 12),
together with the associated increase in mediator levels in
plasma, bronchoalveolar lavage [BALI ( 13), and urine ( 14),
and the ability ofselective antagonists ofhistamine, prostaglan-
din D2, and the sulphidopeptide leukotrienes (LT) to attenuate
the response, has reinforced the initial view that the EAR, like
the skin wheal response to allergen, is mast cell dependent.
Such a mechanism also explains the inhibitory actions of cro-
molyn sodium and nedocromil sodium on the EAR.
Depending on the dose ofthe initial challenge ( 15) approxi-
mately two-thirds ofatopic asthmatic subjects will experience a
second wave of airflow obstruction 4-8 h after challenge ( 16),
which, in being accompanied by a progressive increase in
BHR, has been regarded by some to reflect a more realistic
model of allergen-related clinical asthma. This late asthmatic
response (LAR) is preceded by a transient blood eosinopenia
(17), and between 2 (18) and 96 h (19) postchallenge by an
increase in neutrophils and eosinophils in BAL. While the
LAR is also markedly attenuated by prior administration of
cromolyn sodium (9, 10), corticosteroids (9, 20), and LTD4
antagonists (21 ), the cellular basis for these pharmacological
effects is still not known.
Although BAL and bronchial washings can provide useful
information about cellular and mediator events on the airway
surface, by analogy with diseases of the lung parenchyma, it
may not accurately reflect events occurring within the airway
wall itself. In an attempt to overcome this difficulty we have
applied fibreoptic bronchoscopy to enable local subsegmental
challenge and mucosal biopsy ofasthmatic airways to be under-
taken. By using allergen and saline placebo delivered to sepa-
rate lung segments during the same bronchoscopy procedure,
each subject was able to act as his/her own control. Endobron-
chial subcarinal mucosal biopsies were obtained at 5-6 h after
local allergen and saline challenge and subjected to a immuno-
1. Abbreviations used in this paper: BAL, bronchoalveolar lavage;
BHR, bronchial hyperresponsiveness; EAR, early asthmatic response;
FEV,, forced expiratory volume in 1 s; GMA, glycolmethacrylate;
ICAM, intercellular adhesion molecule; LAR, late asthmatic response;
LT, leukotriene; PC20, provocative concentration of agonist required
to reduce FEV, from baseline by 20%; VCAM, vascular cell adhesion
molecule.
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histochemical analysis to provide a detailed profile ofthe cellu-
lar events associated with this time point.
Methods
Subjects. Six mildly symptomatic asthmatics (three male, three female;
mean age±SEM, 30.5±2.5 yr) were recruited for the study. At the time
of enrolment all the asthmatic subjects had stable pulmonary function
with a forced expiratory volume in I s (FEV1) of > 70% of that pre-
dicted for their age and height. None of the asthmatics were being
treated with inhaled or oral corticosteroids, sodium cromoglycate, or
theophylline. All were using the fl2 agonist salbutamol (albuterol) by
metered dose inhaler when required for relief of symptoms. They had
hyperreactive airways to inhaled methacholine with a geometric mean
provocative concentration of agonist required to reduce FEVy from
baseline by 20% (PC20) of 2.51 (range, 0.25-3.52) mg/ml. The asth-
matic subjects were all atopic as defined by a > 3-mm skin wheal re-
sponse to one or more of five common allergens (Dermatophagoides
pteronyssinus, mixed grass pollen, dog, feathers, and cat dander (Ben-
card, Brentford, UK). All subjects were nonsmokers and none had
experienced an upper respiratory tract infection within 6 wk of investi-
gations. The study conformed to the Declaration of Helsinki, was ap-
proved by the combined Southampton Hospitals and the University
Ethics Subcommittee, and informed written consent was obtained
from each subject.
Screening visit. Subjects attended the laboratory 5 dbeforethebron-
choscopy when allergen skin prick testing, baseline spirometry, and
methacholine reactivity testing were performed. The technique used
for bronchial challenge was adapted from the five-breath procedure of
Chai et al. (22) using an Inspiron nebulizer (CR Bard, Sunderland,
UK). After recording baseline FEV1, subjects inhaled five breaths of
0.9% sodium chloride (saline) from functional residual capacity to to-
tal lung capacity from the nebulizer via a mouthpiece. Measurements
ofFEV1 were made at 1 and 3 min and, provided this value did not fall
by > 10% of baseline, the methacholine provocation was undertaken.
Subjects inhaled increasing doubling concentrations (0.02-16 mg/ml
saline) of methacholine [Sigma Chemical Co., Poole, Dorset, UK] at
5-7-min intervals, with measurements of FEV1 being made 1-3 min
after each inhalation. The stepwise methacholine inhalations contin-
ued until the FEV1 had fallen > 20% of the postsaline value. The con-
centration of methacholine was plotted against the percentage fall in
FEV1 from postsaline baseline, and that concentration causing a 20%
fall in FEV1 (PC20) was derived by linear interpolation of the last two
data points.
The allergen extract (grass pollen or D. pteronyssinus) (Bencard,
Brentford, UK) used for local bronchial challenge was that which pro-
duced the largest wheal response on skin prick testing. In each subject a
skin wheal dose response was undertaken using 10-fold dilutions of
allergen, and a 1:100 dilution of allergen producing a 3-mm wheal
response was chosen for the local bronchial challenge and prepared in
0.9% saline.
Bronchoscopy and local challenge. Fibreoptic bronchoscopy was
undertaken only if the FEV1 was > 70% of patient's predicted value
and the subject's platelet count and clotting studies were within normal
limits. Bronchoscopy was carried out using a standardized protocol
(23). All subjects received atropine (0.6mg intramuscularly), midazo-
lam (2-5 mg i.v.), and salbutamol (2.5 mg by nebulization) 15 min
before the procedure. Oxygen (100%) was administered via nasal
prongs throughout the procedure and oxygen saturation monitored
with a digital oximeter (Minolta, Middlesex, UK). Fibreoptic bron-
choscopy was performed with bronchoscope (IT-20; Olympus Optical
Co., Tokyo, Japan). Care was taken to ensure that the larynx and
upper airways were adequately anesthetized using lignocaine spray
(4%). The bronchoscope was passed through the nares, and up to 12 ml
of lignocaine (1%) was introduced through the bronchoscope into the
larynx and lower airways. The bronchoscope was then wedged into the
anterior division of the right upper lobe (RUL) to undertake a "con-
trol" challenge with 20 ml of sterile saline prewarmed to 370C. The
instrument was then passed into the lateral subdivision of the right
middle lobe (RML) and 20 ml of prewarmed allergen solution in-
stilled. 5 min after introduction ofthe two solutions the appearance of
the airways was observed and photographed to record any airway
narrowing. If widespread bronchoconstriction or severe localized air-
way narrowing occurred, 5-10 ml of salbutamol (2.5 mg/ml) was in-
stilled via the bronchoscope and the procedure terminated.
No specimens were taken at the first bronchoscopy but a second
bronchoscopy was carried out 5-6 h postchallenge using the same pro-
cedure, and biopsies were taken from the two sites using alligator
biopsy forceps. On completion of the procedure, subjects were ob-
served for 3 h and any residual bronchoconstriction was reversed with
nebulized salbutamol.
Postbronchoscopy. Since it was not possible to make an assessment
ofthe physiological response ofthe airwaysjust before the second bron-
choscopy (other than FEV1), subjects were asked to reattend the labora-
tory 1, 3, and 7 d after the local challenges for further measurement of
baseline FEVI and methacholine PC20.
Sample processing. Mucosal biopsies, measuring 0.5-1.5 ,m in di-
ameter, were gently extracted from the forceps with a hypodermic nee-
dle. One biopsy sample was placed in ice-cooled acetone containing the
protease inhibitors phenylmethylsulfonyl fluoride (2 nM) and iodo-
acetamide (2 nM) and cooled rapidly to -20'C. The following day the
sample was transferred into acetone at room temperature for 15 min
followed by methylbenzoyl for a further 15 min. The tissue was then
immersed in glycolmethacrylate (GMA) monomer [Polysciences,
Northampton, UK] at 4VC for 7 h, during which time the GMA solu-
tion was changed three times. Finally, the tissue was embedded in
GMA resin prepared by mixing GMA monomer NN-dimethylaniline
in PEG 400 and benzoyl peroxide, and polymerized overnight at 4°C
(24). The GMA blocks were stored in air-tight containers at -20°C
until used for immunostaining.
A second biopsy for transmission electron microscopy was immedi-
ately placed into glutaraldehyde (3%) for 2 h and then washed in cacco-
dylate/sucrose buffer overnight. The biopsy was postfixed in 2% os-
mium tetroxide in caccodylate buffer for 2 h, rinsed in millipored dou-
ble-distilled water, and incubated in 2% uranyl acetate for a further 1 h.
After dehydration through graded alcohols, clearing in Histosol for 20
min, and infiltration with 50:50 Histosol/Spurr resin for 30 min, the
sample was finally infiltrated in 100% Spurr overnight. The biopsy was
embedded in Spurr resin followed by centrifugation and polymerized
at 60°C for 16 h. 90-nm thick sections were cut using an ultramicro-
tome (C. Reichart, Austria), mounted on uncoated copper grids, and
examined using a microscope (H7000; Hitachi, Tokyo, Japan).
Immunohistochemistry. TheGMA sections were cut at 2-,um thick-
ness and floated onto ammonia water (1:500), picked onto 0.01%
poly-L-lysine glass slides, and allowed to dry at room temperature for
1-6 h. Sections cut for immunostaining of endothelial cell adhesion
molecules (CAMs) were sequential to enable accurate cellular localiza-
tion of immunoreactivity.
Table 1. Monoclonal Antibodies Used in Immunohistochemistry
Name Raised against Species [isotype] Source
6.5B5 ICAM-1 Mouse [IgG,] Dr. D. 0. Haskard
1.2B6 E-selectin Mouse [IgG,] Dr. D. 0. Haskard
1.4C3 VCAM-l Mouse [IgG,] Dr. D. 0. Haskard
TS1/22 CDl la Mouse [IgG,] Prof. T. A. Springer
LFA1/2 CD1 la Mouse [IgG2] Dr. L. Admiral
EN4 Endothelium Mouse [IgG,] SanBio Ltd.
EG2 Eosinophilic Mouse [IgG,] Dako Ltd.
cationic protein
CD3 Lymphocytes Mouse [IgG,] Pharmacia
AAI Mast cell tryptase Mouse [IgG,] Dr. A. Walls
Elastase Neutrophil elastase Mouse [IgG,] Pharmacia
Mouse Immunoglobulin control MoAb SigmaChemical Co.
IgG,
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Endogenous peroxidase was blocked using a solution of 0.1% so-
dium azide and 0.3% hydrogen peroxide, followed by three rinses in
Tris-buffered saline(TBS) adjusted at pH 7.6. Undiluted culture su-
pernatant consisting of10%, Dulbecco's MEM fetal calf serum, and 1%
bovine serum albumin was applied for 30 min followed by a primary
mAb, and further incubation at room temperature overnight. The
mAbs used and their sources of origin are displayed in TableI. After
rinsing, biotinylated rabbit anti-mouse IgG Fab (Dako Ltd., High Wy-
combe, UK) was applied to the section for 2 h and followed by the
streptavidin-biotin horseradish-peroxidase complex (Dako Ltd.) for a
further 2 h. After rinsing in TBS, amino-ethyl carbamazole (AEC) in
acetate buffer (pH 5.2) and hydrogen peroxide were used as substrate
to develop a peroxide-dependent red color reaction (24). The sections
were counterstained with Mayer's hematoxylin.
Quantification ofimmunostaining. Inflammatory cells staining posi-
tively with each mAb were counted in the submucosa, excluding muco-
sal glands and blood vessels. The total area of submucosa was calcu-
lated by delineating the area of the section on a video interactive dis-
play system (VIDS2) and using software for measurement of area
(Analytical Measurement Systems, Cambridge, UK), the results being
expressed as the number of cells per square millimeter of submucosa.
Cells staining positively for LFA- I were also counted in five randomly
chosen high-power fields of the epithelium and expressed as cells per
millimeter of epithelium.
In the case of the CAMs expressed on the endothelium, we have
used a technique of quantification that relates the number of blood
vessels stained with a specific mAb to the total complement of the
microvasculature. Briefly, the number of vessels present in the section
stained with the vessel marker EN4 (SanBio, Uden, The Netherlands)
was taken as the full complement of vessels present in this section (25).
The number of vessels staining positive for specific adhesion molecules
in consecutive sections were expressed as a percentage ofthe total vessel
population. This index denoted the proportion of vessels expressing a
particular adhesion molecule at a detectable level for a particular anti-
body titration used. All slides were analysed in a "blinded" fashion.
Statistical analysis. As the cell and CAM counts were not normally
distributed, the Mann Whitney U test was used when analyzing differ-
ences between groups, and the Wilcoxon paired rank tests for data at
different time points within the same group. The Spearman's rank
coefficient was used to investigate the relationship between cell counts
and adhesion molecule expression.
Results
Airway physiology
Within 3-5 min, all six subjects visibly reacted to the local
instillation of allergen by bronchoconstricting, the challenged
segmental bronchus producing a range of airway narrowing
from 30 to 95%, in contradistinction to the saline-challenged
control site at which there was no visible change in airway
caliber. The spirometry traces obtained just before the second
bronchoscopy were technically unsatisfactory in four of the six
subjects on account of drowsiness from the previous sedating
medication. In the two subjects who produced good records,
FEV1 6 h after local allergen and saline challenge was no differ-
ent from the first prebronchoscopy FEVY. Although allergen
was only instilled into one lung subsegment, it produced mea-
surable changes in overall indices of lung function. Thus, 24 h
after allergen instillation the mean±SEM predicted FEV, fell
from 100.1±4.1 to 88.1±5.6% (P < 0.01), indicative of a per-
sistent late phase response. Further evidence of disordered air-
way function after allergen instillation was obtained by finding
a significant (P < 0.05) reduction in the geometric mean meth-
acholine PC20 from a prechallenge value of 2.51 (range, 0.25-
3.52) to 1.33 (range, 0.1 1-2.45) mg/ml at 24 h. However, by 7
d postchallenge both the FEVY and PC20 had returned to base-
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Figure 1. Changes in (a) percent predicted FEVI and (b) methacho-
line PC20 during the various studied time points before and after the
allergen challenge. Horizontal lines denote median values.
line levels of 97.8±6.31 and 2.9 mg/ml, respectively (NS)
(Fig. 1).
Bronchial biopsies
LEUKOCYTE PHENOTYPES
Immunohistochemistry. The cell-specific mAbs identified a
mixed inflammatory cellular infiltrate in association with the
late phase response. Staining for elastase clearly demonstrated
the presence of large numbers of neutrophils in the submucosa
after allergen challenge (Fig. 2, a and b). The median neutro-
phil count at the allergen-exposed site was 265.5 (range, 50-
2,043)/mm2 compared with 46 (range, 17-88)/mm2 at the
saline-challenged site (P <0.03) (Fig. 3). Further inspection of
the neutrophils under high-power light microscopy demon-
strated a pericellular haze of elastase immunostaining indica-
tive of its extracellular release. The number of infiltrating neu-
trophils correlated positively with the increase in endothelial
expression of ICAM-I (r, = 0.59) but not E-selectin (r,
= 0.27).
In addition to neutrophils, eosinophils identified immuno-
histochemically by their granule content of eosinophil cationic
protein were also seen to infiltrate the allergen-challenged mu-
cosa, with numbers in the saline- and allergen-challenged mu-
cosa being 8.5 (range, 0-27) and 45.5 (range, 16-245 )/mm2,
respectively (P < 0.025). The eosinophil increases correlated
with those of the neutrophils (r, = 0.82, P < 0.05), but no
correlation was found with the extent of expression of any of
the three CAMs. Allergen exposure also stimulated an increase
in submucosal tryptase-positive mast cells from a median of
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Figqrui 2. Light microscopy micrographs of GMA-embedded sections immunostained with mAbs to (I) neutrophil elastase, (2) EG2+ eosino-
phils. (3) trvptase+ mast cells. and (4) CD3+ lymphocytes from (a) saline-challenged site and (h) allergen-challenged site (x400).
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Figure 3. Changes in submucosal leukocytes between saline- and allergen-challenged sites. Horizontal lines denote medians (log scales).
14.5 (range, 8-35 )/mm2 in the saline-challenged segment to 49
(range, 17-60)/mm2 (P < 0.03) at the allergen-challenged site.
T lymphocytes staining positively for CD3 also increased in
the submucosa after exposure to allergen but not saline, with
counts of 64.5 (range, 2-333) and 107.5 (range, 30-717)/
mm2, respectively (P < 0.03), but while both the CD4' and
CD8 + lymphocyte subsets showed a trend towards increasing
this failed to reach statistical significance (45.4 and 59.2 for
CD4+, and 48.7 and 53.2 for CD8+ lymphocytes).
Electron microscopy. Electron microscopy confirmed the
presence of many different cell types infiltrating the airways
after allergen challenge, and included platelets (not identified
immunohistochemically). In confirmation of the immunohis-
tochemical findings, after allergen exposure, neutrophils de-
pleted in their granules provided additional evidence that these
cells were secreting their mediators (Fig. 4 a). Mast cells (Fig. 4
b) and eosinophils also showed features of degranulation as
judged by both classical and piecemeal secretion. Most eosino-
phils also exhibited reduced electrondensity ofthe granule crys-
talloids containing major basic protein (Fig. 4 c). The epithe-
lium and submucosa appeared oedematous as evidenced by
separation of columnar and basal cells.
ADHESION MOLECULES
Glycolmethacrylate sections provided excellent embedding me-
dium to demonstrate immunoreactive epitopes with well-pre-
served microanatomy and cell morphology. All the mAbs to
E-selectin, intercellular (I) CAM- 1, and vascular (V)CAM- 1
produced clear immunostaining ofthe mucosal microvascula-
ture. Anti-ICAM- 1 also produced scant staining of parts of the
basal layer of the bronchial epithelium and of occassional mu-
cosal leukocytes. Both E-selectin and to a greater extent ICAM-
1 were constitutively expressed on the microvascular endothe-
lium, however, only a very low level of VCAM-1 expression
was observed.
Differences were apparent when the pattern of immuno-
staining for the three endothelial adhesion molecules between
the allergen and saline challenged bronchi were compared (Fig.
5, a and b). When expressed as a percentage of the total vessel
complement, allergen exposure resulted in a median twofold
increase in the number of vessels expressing E-selectin from
18.4% (range, 3.8-35.7%) after saline compared with 36.3%
(range, 15.3-68.4%) after allergen (P < 0.005) (Fig. 6). Simi-
larly, allergen also upregulated the expression ofICAM- 1 from
a basal saline-challenged level of48.8% (range, 30.7-62.8%) to
70.2% (range, 38-87.3%) (P < 0.05). This ICAM-l upregula-
tion was correlated with the decrease in FEV, observed in the
first 24 h (r, = 0.9; P < 0.05). In contrast, allergen provocation
had no significant effect on VCAM- 1 expression at the 5-6-h
time point (2.3% [range, 0-5% ] vs. 2.4% [range, 0-12% ] [NS]).
Both in the epithelium and in the submucosa of the saline-
challenged airways occasional leucocytes immunostaining for
the cell surface integrin LFA- 1 were observed. Exposure to al-
lergen produced a four- to sixfold increase in the number of
leukocytes expressing cell surface LFA-l (Fig. 7 ), cell medians
increasing from 19.9 (range, 2.4-48.4) to 160.5 (range, 36.8-
216.4)/mm2 in the submucosa (P < 0.01) and 0.8 (range,
0-2.4) to 3.8 (range, 2.4-4.2)/mm length of basement mem-
brane in the epithelium (P < 0.01 ) (Fig. 8). The allergen-pro-
voked increase in submucosal LFA- 1 leukocyte infiltrate with
allergen exposure correlated with the extent ofexpression of its
ligand ICAM- 1 (r. = 0.70), but not E-selectin or VCAM- 1 (r,
= 0.30; r, = 0.41). It also correlated with the decrease in FEV,
observed in the first day postchallenge (r, = 0.83; P < 0.05).
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Figure 4. (a) Electron micrograph of a partially degranulated neutro-
phil within area of edematous bronchial epithelium from allergen-
challenged site (X7,000). (b) Electron micrograph of mast cell with
the characteristic scroll-like appearance of granules and some degran-
ulated granules (x 17,000). (c) Electron micrograph of partially de-
granulated eosinophil from allergen-challenged site (X8,500).
Discussion
Delivery of allergen directly on the airway surface via the fi-
breoptic bronchoscope has provided a unique opportunity for
defining the cellular events associated with the late asthmatic
response 5-6 h postchallenge. Although it was not possible to
make detailed measurements of pulmonary function at the
same time as the bronchial biopsy, all the subjects experienced
a drop in spirometry 24 h postallergen and an increase in meth-
acholine responsiveness that returned to baseline by 7 d. When
compared with the saline-challenged site, allergen also caused a
marked increase in the expression of CAMs, specifically E-se-
lectin and ICAM- 1, but not VCAM- 1. Upregulation of endo-
thelial CAMs was associated with a marked increase in the
number of leukocytes expressing the f2 integrin LFA-l that
correlated with ICAM- 1 expression, suggesting a mechanism
for leukocyte recruitment. The cellular infiltrate was pleomor-
phic consisting predominantly of neutrophils and eosinophils
but also containing increased numbers of T-cells and mast
cells. Electron microscopy confirmed that the neutrophils, eo-
sinophils, and mast cells were activated for mediator secretion.
These data provide substantial evidence for leukocyte recruit-
ment and activation as a response to allergen on the asthmatic
airways and demonstrate the importance of upregulation of
leukocyte-endothelial CAMs as an integral component ofthis.
A surprising finding in this study was the extensive neutro-
phil infiltration of the airway 5-6 h after allergen exposure,
since the asthmatic response to allergen is frequently cited as
being largely eosinophil dependent. While saline-challenged
airways contained a few neutrophils, these may have been re-
cruited secondary to nonspecific irritation ofthe airways by the
bronchoscope and saline. After allergen exposure the level of
neutrophil influx varied widely between subjects for reasons
that are not clear. However, in all cases the cells appeared to be
in a secretory mode when assessed both by light and transmis-
sion electron microscopy. Although not widely referred to,
others have noted neutrophils in BAL 6-48 h after allergen
challenge of asthmatic airways (19, 26). Recently, Gundel et
al. (27) have suggested that the neutrophil plays a dominant
role in the LAR produced at 6 h by antigen challenge of
Ascaris-sensitised monkeys. Neutrophil chemotactic activity
has been described in the serum of asthmatics in association
with the LAR, but apart from being heat stable and of high
molecular weight, this has been poorly characterized (28). A
number of well-defined chemoattractants for neutrophils have
been described, including C5a (29), platelet-activating factor
(PAF) (30), leukotriene B4 (31), tryptase (32), and members
ofthe IL-8 family (33). However, while a case may be made for
each ofthese contributing to the airway neutrophilia observed,
at the time of writing, the role of anyone of these has not been
defined. This study has also provided morphological evidence
for neutrophil degranulation after allergen challenge. The re-
lease ofsuch preformed mediators as elastase, cathepsin G, and
myeloperoxidase could contribute to the loosening ofthe inter-
cellular matrix, thereby facilitating edema formation and de-
tachment of bronchial epithelial cells (34). In addition, the
neutrophil is also an important source of broncho- and vaso-
active autocoids, including PAF, thromboxane A2 (TxA2), to-
gether with an array of other prostanoids (35). The neutrophil
has been associated with the late phase response associated
with occupational asthma caused by isocyanates ( 18). This
study now provides evidence of a role for this cell in the aller-
gen-dependent response. The reason why this cell has been
overlooked in the past can probably be explained on the basis
that bronchoscopy studies after allergen challenge in asthma
have largely been undertaken 24-48 h postchallenge when the
late phase obstructive response has largely recovered, even
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FigureS5 Light microscopy micrographs of GMA-embedded sequential sections immunostained with mAbs to (1) vascular endothelium [EN4J,
(2) ICAM- 1, and (3) E-selectin from (a) saline-challenged site and (b) allergen-challenged site (X400).
though the airways remain hyperreactive to agents such as his-
tamine and methacholine.
Consistent with many BAL studies carried out at different
time points after allergen challenge ( 14, 19, 26, 36), we have
also observed a significant increase in eosinophil numbers 5-6
h after segmental challenge with allergen. Although most ofthe
studies have focused at time points 24-96 h postchallenge,
Lam et al. (37) and Metzger et al. ( 19) have reported an airway
eosinophilia in BAL at 2 and 4 h, respectively. Durham et al.
( 17) have also shown a transient early blood eosinopenia soon
after allergen challenge compatible with their removal from the
circulation by entrapment within the bronchial microvascula-
ture. While in this study we have been able to demonstrate
morphological evidence for eosinophil activation, others have
shown that allergen challenge is accompanied by release of eo-
sinophilic peroxidase (27) and the secreted form of eosinophil
cationic protein ( 14). At the 5-6-h time point sampled in this
study, the magnitude of the eosinophil response was less than
that observed for neutrophils although cell number alone may
have little to do with either the range or magnitude ofvaso- and
broncho-active mechanisms contributing to airway dysfunc-
tion of the continuing asthmatic response.
The release ofmediators from the mast cell is considered to
be largely responsible for the EAR, although this mechanism is
not thought to contribute to the LAR. We were therefore sur-
prised to find a highly significant increase in the number of
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mast cells, identified by their granule content of tryptase, that
had moved into the submucosa 5-6 h postallergen. It seems
most unlikely that these cells are recruited from the circulation
or matured rapidly from resident mast cell precursors. A more
plausible explanation for the increase in mast cell number is
migration ofthese cells to the airway surface from deeper in the
airway wall, where they are more likely to be activated by aller-
gen. Not much is known about mast chemotaxis, although re-
cently Thompson et al. (38) have shown that laminin and fibro-
nectin fragments are chemoattractant to cultured murine mast
cells. In Bazenji greyhound dogs, Turner et al. (39) have shown
that mast cell numbers increase in the superficial aspects ofthe
airway within 1 h of local allergen stimulation, indicating that
rapid migration of mast cells in response to allergen is possible.
Crimi et al. (40) have also observed an increase in submucosal
mast cell numbers 24 h but not 4 h after allergen inhalation in
asthmatics developing a late-phase reaction. Interestingly, Diaz
et al. (26) noticed that there was a decrease in their BAL mast
cell numbers in allergen-challenged bronchi at 7 h postchal-
lenge, and suggested that this might be due to these cells being
retained by increased adherence to acutely inflammed sites
within the bronchial mucosa. The significance of the apparent
mucosal mast cell hyperplasia at this time point clearly requires
more careful evaluation since mast cells, in addition to neutro-
phils and eosinophils, are an important source of mediators,
including cytokines.
In addition to an influx of mediator-secreting cells, allergen
provocation resulted in an influx ofCD3 + T lymphocytes. Re-
cruitment ofT lymphocytes has been clearly described in asso-
ciation with allergen-induced late phase reactions in the skin
(41, 42), with a case being presented that these cells augment
the allergic inflammatory response through secretion of spe-
cific cytokines (43). A subset ofhelper T cells, designated Th 2,
respond to allergen by secreting IL-3, IL-4, IL-5, IL-6, and
GM-CSF involved in mast cell growth and priming (IL-3, IL-
4), eosinophil recruitment and priming (IL-5, GM-CSF), and
isotype switching ofB cells to IgE synthesis (IL-4, IL-6). Thus,
it seems likely that the T cell infiltrate seen 6 h after allergen
instillation represents a mechanism for amplifying and pro-
longing the inflammatory response.
The mechanisms whereby leukocytes are selectively re-
moved from the microvasculature and recruited into sites of
inflammation have recently been clarified with the identifica-
Figure 8. Changes in (a) submuco-
sal and (b) epithelial LFA-l + leuko-
cytes between saline- and allergen-
challenged sites. Horizontal lines
afergen denote medians.
tion ofthe roles played by specific leukocyte-endothelial adhe-
sion molecules. This study has shown an upregulation of E-se-
lectin and ICAM- 1 but not VCAM- 1 5-6 h after allergen chal-
lenge. Previous methods attempting to quantify adhesion
molecules expression in tissue biopsies have relied upon semi-
quantitative subjective grading of immunoreactivity, which is
subject to considerable intraobserver variation. To circumvent
this we opted to express CAM expression on the endothelium
as a percentage of the total vessel complement. An alternative
approach would be to count the number of endothelial cells
expressing a particular CAM, but this would require immuno-
electron microscopy to produce reliable results. On human um-
bilical vein endothelial cells in vitro, E-selectin is upregulated
by IL- 1 and TNFa, peaking in expression within 4 h ofstimula-
tion (44). Although ICAM- 1 and VCAM- 1 have similar time
courses ofupregulation in vitro to each other, in our study only
the former showed any such increase in expression. The mecha-
nisms responsible for the dissociation ofICAM- 1 from VCAM-
1 expression in vivo are not at present clear. This pattern of
expression in vivo is in agreement with that observed in the
skin of atopic subjects 6 h after intradermal allergen injection
(45). Interestingly, Bentley et al. (46) have recently reported
an increased bronchial mucosal expression of VCAM-1 24 h
postallergen inhalation. Together these observations might be
interpreted as an early upregulation of E-selectin and ICAM- 1
being responsible for the mixed eosinophil, neutrophil, and T
cell response at 5-6 h, while VCAM- 1 increasing up to 24 h
may account for the more selective eosinophil and T cell re-
sponse at this later time point consequent upon an interaction
with the leukocyte integrin VLA-4 (a431 ) (47). The findings
of upregulated E-selectin and ICAM- 1 are similar to those of
Wegner et al. (48) and Gundel et al. (49), who have shown that
mAbs to ICAM- 1 and E-selectin, respectively, attenuated leu-
kocyte recruitment and the disordered airway function ob-
served in Ascaris-sensitised monkeys after allergen exposure.
The mechanisms causing upregulation of adhesion mole-
cules on the airway microvasculature after allergen exposure
are at present speculative. In vitro studies point to an impor-
tant role played by various stimulatory cytokines. A number of
studies have shown that bone marrow-derived murine mast
cells and mast cell lines generate a range ofcytokines, including
IL-3, IL-4, IL-5, IL-9, and TNFa, after IgE-dependent stimula-
tion (50), and in human bone marrow, Piccinni et al. (51)
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have described a population of FcERI-bearing non-B-non-T
cells that generate a similar spectrum ofcytokines upon recep-
tor cross-linkage. Walsh et al. (52) have reported the presence
of preformed TNFa in mast cells ofhuman skin and its release
with allergen challenge, and together with Klein et al. (53),
have suggested that upregulation of E-selectin on endothelial
cells by antigen in human skin organ culture relates to the
release ofTNFa from IgE-triggered mast cells. Similarly, Brad-
ding et al. (54) have recently reported the localization and
immunologic release of IL-4 from both human lung and skin
mast cells. IL-4 is a selective stimulus for upregulating the ex-
pression of VCAM-1 on endothelial cells (55), and as such
might be implicated in the selective recruitment ofeosinophils
and T cells but not neutrophils 24 h after allergen exposure.
Finally, we have also observed a correlative increase ofLFA- 1
leukocytes into the submucosa and epithelium ofthe bronchial
biopsies at the allergen-challenged site. This probably repre-
sents most of the infiltrating leukocytes that used this ,B2 inte-
grin as one of adhesion molecules to adhere to and transmi-
grate from the circulation into the bronchial mucosa.
The decrease in baseline FEV, and increase in methacho-
line responsiveness of the airways 24 h after segmental chal-
lenge with allergen suggests that the challenge initiated events
that extended beyond the local site by that time point. For
technical reasons it was not possible to obtain reliable FEVI
readings 6 h postallergen instillation in four subjects, although
in two, in whom good measurements were obtained, their base-
line FEVI had not fallen at 6 h. This suggests that the uniform
changes in airway dysfunction observed at 24 h related to
neural reflex mechanisms or more likely a secondary systemic
response. It would clearly be of interest to observe the biopsy
appearance ofthe saline challenged site at 24 h for comparison
with the minimal changes seen at 6 h.
In conclusion, we have shown that at 5-6 h after the expo-
sure of allergic asthmatic airways to specific allergen, there oc-
curs an upregulation ofE-selectin and ICAM- 1 that isaccompa-
nied by an influx of LFA-l + leukocytes into the submucosa
and epithelium. These cells include neutrophils and eosino-
phils, whose mediators could account for the reduced airway
caliber and BHR associated with allergen-induced LAR. A
knowledge of the importance of the mechanisms leading to
adhesion molecule upregulation and the recruitment ofinflam-
matory cells in this model presents an exciting opportunity for
the development ofnew pharmacological agents for treatment
of allergen-triggered asthma.
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